IceCure Medical (NASDAQ:ICCM – Get Free Report) and TransMedics Group (NASDAQ:TMDX – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.
Analyst Ratings
This is a summary of current recommendations for IceCure Medical and TransMedics Group, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IceCure Medical | 1 | 1 | 2 | 0 | 2.25 |
| TransMedics Group | 0 | 7 | 5 | 0 | 2.42 |
IceCure Medical presently has a consensus target price of $30.00, suggesting a potential upside of 4,125.35%. TransMedics Group has a consensus target price of $113.30, suggesting a potential upside of 22.56%. Given IceCure Medical’s higher possible upside, research analysts plainly believe IceCure Medical is more favorable than TransMedics Group.
Volatility & Risk
IceCure Medical has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 2.14, indicating that its share price is 114% more volatile than the S&P 500.
Profitability
This table compares IceCure Medical and TransMedics Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IceCure Medical | -427.67% | -174.26% | -112.58% |
| TransMedics Group | 19.85% | 13.30% | 4.93% |
Valuation and Earnings
This table compares IceCure Medical and TransMedics Group”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IceCure Medical | $3.95 million | 0.62 | -$15.06 million | ($8.52) | -0.08 |
| TransMedics Group | $727.65 million | 4.41 | $190.29 million | $3.69 | 25.05 |
TransMedics Group has higher revenue and earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
0.6% of IceCure Medical shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by company insiders. Comparatively, 6.9% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
TransMedics Group beats IceCure Medical on 13 of the 14 factors compared between the two stocks.
About IceCure Medical
IceCure Medical Ltd. is an Israel-based medical technology company focused on minimally invasive cryoablation treatments for cancerous and benign tumors. Its technology uses extremely cold temperatures, generated by liquid nitrogen, to destroy targeted tissue while limiting damage to surrounding areas. The company’s primary product is the ProSense Cryoablation System, which consists of a console, cryoprobes and related components. The system is designed to freeze and ablate tumors through a percutaneous procedure, generally under image guidance.
About TransMedics Group
TransMedics Group, Inc. is a medical technology company focused on improving organ transplantation. Its Organ Care System (OCS) is a portable platform that perfuses donor organs with warm, oxygenated blood and nutrients while they are outside the body. The company offers OCS systems for donor hearts, lungs and livers, along with related consumables and services. The company also operates the National OCS Program in the United States, an integrated offering that combines its technology with organ procurement and transportation services.
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.
